Only about 20% of employers with 200 or more workers currently cover weight-loss drugs, leaving roughly half of commercially insured patients unable to start or stay on therapy
Read more at Penn Medicine News.
Publicados los resultados en The Lancet Diabetes and Endocrinology, la muestra se compar con la poblacin que recibi un placebo
(5.1) Risk factors include renal impairment, concomitant use of certain drugs, age 65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment
When too many are released, they can lead to inflammation in muscles or joints
The gut microbiome's influence on systemic inflammation, metabolic health, immune function, and even brain aging is now documented well enough to take seriously as a therapeutic target